214 related articles for article (PubMed ID: 12941814)
1. Specificity of cyclin D1 for androgen receptor regulation.
Petre-Draviam CE; Cook SL; Burd CJ; Marshall TW; Wetherill YB; Knudsen KE
Cancer Res; 2003 Aug; 63(16):4903-13. PubMed ID: 12941814
[TBL] [Abstract][Full Text] [Related]
2. A central domain of cyclin D1 mediates nuclear receptor corepressor activity.
Petre-Draviam CE; Williams EB; Burd CJ; Gladden A; Moghadam H; Meller J; Diehl JA; Knudsen KE
Oncogene; 2005 Jan; 24(3):431-44. PubMed ID: 15558026
[TBL] [Abstract][Full Text] [Related]
3. D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability.
Knudsen KE; Cavenee WK; Arden KC
Cancer Res; 1999 May; 59(10):2297-301. PubMed ID: 10344732
[TBL] [Abstract][Full Text] [Related]
4. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
5. ACTR/AIB1/SRC-3 and androgen receptor control prostate cancer cell proliferation and tumor growth through direct control of cell cycle genes.
Zou JX; Zhong Z; Shi XB; Tepper CG; deVere White RW; Kung HJ; Chen H
Prostate; 2006 Oct; 66(14):1474-86. PubMed ID: 16921507
[TBL] [Abstract][Full Text] [Related]
6. CDC25A functions as a novel Ar corepressor in prostate cancer cells.
Chiu YT; Han HY; Leung SC; Yuen HF; Chau CW; Guo Z; Qiu Y; Chan KW; Wang X; Wong YC; Ling MT
J Mol Biol; 2009 Jan; 385(2):446-56. PubMed ID: 19013180
[TBL] [Abstract][Full Text] [Related]
7. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
[TBL] [Abstract][Full Text] [Related]
8. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
10. Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor.
Chesire DR; Isaacs WB
Oncogene; 2002 Dec; 21(55):8453-69. PubMed ID: 12466965
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
12. Sterol regulatory element-binding protein-1c represses the transactivation of androgen receptor and androgen-dependent growth of prostatic cells.
Suh JH; Gong EY; Kim JB; Lee IK; Choi HS; Lee K
Mol Cancer Res; 2008 Feb; 6(2):314-24. PubMed ID: 18245227
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
14. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells.
Cao X; Qin J; Xie Y; Khan O; Dowd F; Scofield M; Lin MF; Tu Y
Oncogene; 2006 Jun; 25(26):3719-34. PubMed ID: 16449965
[TBL] [Abstract][Full Text] [Related]
15. Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells.
Yuan H; Gong A; Young CY
Carcinogenesis; 2005 Apr; 26(4):793-801. PubMed ID: 15661808
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation in the androgen receptor gene promoter region in rat prostate cancers.
Takahashi S; Inaguma S; Sakakibara M; Cho YM; Suzuki S; Ikeda Y; Cui L; Shirai T
Prostate; 2002 Jun; 52(1):82-8. PubMed ID: 11992622
[TBL] [Abstract][Full Text] [Related]
17. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
18. Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways.
Yang Y; Ikezoe T; Takeuchi T; Adachi Y; Ohtsuki Y; Koeffler HP; Taguchi H
Oncol Rep; 2006 Jun; 15(6):1581-90. PubMed ID: 16685399
[TBL] [Abstract][Full Text] [Related]
19. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis.
Mulholland DJ; Read JT; Rennie PS; Cox ME; Nelson CC
Oncogene; 2003 Aug; 22(36):5602-13. PubMed ID: 12944908
[TBL] [Abstract][Full Text] [Related]
20. Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth.
Minamiguchi K; Kawada M; Ohba S; Takamoto K; Ishizuka M
Mol Cell Endocrinol; 2004 Feb; 214(1-2):175-87. PubMed ID: 15062556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
